Status:
COMPLETED
The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants
Lead Sponsor:
Lallemand Health Solutions
Collaborating Sponsors:
Clinique Ovo
Conditions:
Pregnancy
Eligibility:
FEMALE
18-39 years
Phase:
PHASE2
Brief Summary
This phase 2 study evaluates the effect of perinatal use of probiotics on the number of diagnosed viral, bacterial and fungal infections in pregnant women and on the maintenance of a health pregnancy....
Detailed Description
Throughout pregnancy women undergo many biological changes, including alterations in their microbiota. These infections can exacerbate pregnancy complications and increase the risk of preeclampsia and...
Eligibility Criteria
Inclusion
- Healthy pregnant women
- Less than 28 weeks of gestation (3rd trimester)
- ≥18 to \<40 years old
- Singleton gestation
- Availability and willingness to come in for morning visits
- Planning to breastfeed
- Willing to complete questionnaires, records, and diaries associated with the study and to complete all clinical visits
- Willing to discontinue consumption of fermented foods (e.g. foods that contain probiotics such as Kefir, pickles, etc.) or probiotics (e.g. yogurts with live active cultures or probiotic supplements)
- Able to provide informed consent
Exclusion
- Known gestational diabetes or diabetes type 1 or 2
- Known blood/bleeding disorders
- Known liver and kidney disorders
- Known unstable cardiovascular diseases
- Women with a personal history of or currently diagnosed with preeclampsia
- Suffering from neurological diseases (e.g. Alzheimer's disease, Parkinson's disease, epilepsy, etc.)
- Suffering from gastrointestinal diseases (e.g. gastric ulcers, Crohn's disease, ulcerative colitis, etc.)
- Current symptoms of depression or experienced depressive symptoms in the past 2 years
- Maternal history of second trimester loss
- Women diagnosed HIV Positive or with Hepatitis B or C
- Known fetal abnormality
- Daily use of probiotic product within 2 weeks of the screening visit. The potential participant could be eligible to participate after a 2-week wash-out period
- Use of any antibiotic drug within 1 month of screening. The potential participant could be eligible to participate after a 2-week wash-out period
- Smoking, alcohol consumption or drug use during pregnancy
- History of alcohol or substance abuse six months prior to screening
- Allergies to milk, soy, or yeast
Key Trial Info
Start Date :
October 23 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2022
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03310853
Start Date
October 23 2017
End Date
May 20 2022
Last Update
February 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique OVO
Montreal, Quebec, Canada